Does IL-23/Th17-driven mucosal inflammation destabilize the gut microbiome and increase intestinal permeability, promoting systemic inflammation?

Context and Overview

The interleukin-23 (IL-23)/T-helper 17 (Th17) pathway is a central regulator of mucosal immunity, maintaining a delicate balance between protective host defense and pathological inflammatory tissue damage. Under steady-state conditions, this immunological axis preserves barrier function and shapes a healthy commensal microbiome. However, dysregulation of this system leads to a feed-forward inflammatory cascade that compromised the gut barrier, causing systemic clinical downstream effects.

Thematic Analysis of the Evidence

1. Gut Mucosal Immune Regulation by the IL-23/Th17 Axis

• Physiological Homeostasis: Under baseline conditions, IL-23 is produced by myeloid cells (such as dendritic cells and macrophages) and binds to the IL-23 receptor (IL-23R) on CD4+ Th17 cells and group 3 innate lymphoid cells (ILC3s). This signaling cascade drives the transcription and secretion of the effector cytokines IL-17 and IL-22.
• Barrier Maintenance: These cytokines bind to receptors on intestinal epithelial cells (IECs) and Paneth cells, activating STAT3-dependent transcription of protective proteins. This process promotes the synthesis of critical tight junction proteins, mucus, and antimicrobial peptides (AMPs)—such as Reg3$\beta$, Reg3$\gamma$, and defensins—which collectively secure the physical barrier and prevent pathogen invasion.
• Epithelial Epitopes: Epithelial cells also express IL-23R directly; this signaling promotes the secretion of chemoattractants (e.g., Reg3$\beta$) that recruit IL-22-producing neutrophils to the lamina propria, optimizing the local protective microenvironment.

2. Th17-Biased Inflammation and Microbiome Dysbiosis

• Altered Selective Pressure: When the IL-23/Th17 axis is chronically overactivated, the resulting sustained, high levels of IL-17 and IL-22 alter the pattern of AMP secretion (including RegIII$\beta$, RegIII$\gamma$, $\beta$-defensins, lipocalin-2, and S100 proteins). This altered cocktail of antimicrobials exerts selective bactericidal pressure, culling susceptible, beneficial commensal clades.
• Epithelial Glycosylation Shifts: Under inflammatory conditions, IL-17 and IL-22 alter the glycosylation and fucosylation profiles of the mucosal epithelium. This structural modification changes the available carbohydrate niches, favoring the outgrowth of opportunistic pathobionts over protective symbiotic bacteria and destabilizing the overall microbiome structure.

3. Increased Permeability and Systemic Inflammation

• Tight Junction Disruption: In chronic inflammatory states, the homeostatic, protective role of Th17 cytokines is lost. Pathogenic Th17-biased inflammation compromises the gut barrier by altering tight junction molecular architecture. Notably, it upregulates pore-forming claudin-2, significantly increasing paracellular permeability (commonly termed "leaky gut").
• Antigen Translocation: The resulting breakdown of the epithelial barrier allows the uncontrolled translocation of luminal antigens and pathogen-associated molecular patterns (PAMPs), such as lipopolysaccharide (LPS) and bacterial DNA, into the lamina propria and portal circulation.
• Systemic Inflammatory Cascade: Upon entering systemic circulation, translocated LPS (endotoxemia) binds to Toll-like receptor 4 (TLR4)/MyD88 complexes on immune cells. This triggers a systemic pro-inflammatory cascade characterized by the release of acute-phase reactants (e.g., C-reactive protein) and inflammatory cytokines (including IL-6 and IL-1$\beta$), driving systemic inflammatory pathology.

Bottom line

The clinical claim is fully supported. The IL-23/Th17 axis acts as a primary coordinator of the intestinal barrier and local immunity. When chronically overactivated, it transitions from a protective pathway to a pathogenic driver, causing selective microbiome dysbiosis, upregulating pore-forming claudin-2 to increase intestinal permeability, and enabling the systemic translocation of LPS to trigger systemic inflammatory cascades.